Project Grant K08HL177429
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $160K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $248,999 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate reduced hypusination of EIF5A as a mechanism of heart failure with preserved ejection fraction (HFPEF). The research addresses mechanisms underlying HFPEF, which affects over half of heart failure patients but...
- The National Heart, Lung, and Blood Institute awarded the University of Texas Southwestern Medical Center $811,633 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of endotrophin in heart failure with preserved ejection fraction. The recipient will conduct basic and translational research examining endotrophin (ETP), a bioactive cleavage product of collagen VI, as a molecular driver of heart failure with preserved ejection fraction...
- The National Heart, Lung, and Blood Institute awarded East Tennessee State University $536,447 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026, to investigate mechanisms of macrophage retention in the extracellular matrix during atherosclerosis development. The project examines how oxidation of polyunsaturated fatty acids—including docosahexaenoic acid, arachidonic acid, and linolenic acid—generates adhesive substrates in vascular tissue that anchor...
- The National Heart, Lung, and Blood Institute awarded $2.609 million to Vanderbilt University Medical Center on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the pathophysiological mechanisms of mitochondrial cyclophilin D acetylation in vascular dysfunction and hypertension through September 29, 2028. The project will define cell-specific pathogenic mechanisms of endothelial and smooth muscle cyclophilin D acetylation in hypertension and vascular...
- The National Heart, Lung, and Blood Institute awarded Yale University $838,491 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify novel gene variants that drive endothelial cell activation during atherosclerotic cardiovascular disease. The recipient will elucidate mechanisms by which gain-of-function defects in ZFYVE21, an endosome-associated protein highly expressed in endothelial cells, contribute to endothelial cell activation and exacerbate...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,971 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage 12-lipoxygenase signaling as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research program establishes 12-lipoxygenase (12-LOX), an enzyme that converts arachidonic acid into bioactive lipid mediators, as a master regulator of HFPEF progression...
- The National Heart, Lung, and Blood Institute awarded Duke University $778,772 on August 18, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolic and contractile dysfunction in heart failure with preserved ejection fraction. The research focuses on understanding the mechanistic link between mitochondrial impairment and loss of muscle strength and power in HFPEF, a systemic disorder affecting 3–4 million U.S. patients predominantly older women. The...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Vanderbilt University Medical Center $341,280 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year mentored career development project investigating apoptosis resistance mechanisms in pulmonary arterial smooth muscle cells. Dr. Niedermeyer, under mentorship from Dr. Larissa Shimoda and Dr. Mahendra Damarla, will conduct hands-on laboratory research, complete...
- The National Heart Lung and Blood Institute awarded The Johns Hopkins University $638,176 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombospondin-1 (TSP-1) as a therapeutic target in heart failure with preserved ejection fraction (HFPEF). The research focuses on identifying sex-specific mechanisms underlying cardiac structural changes in HFPEF, with specific emphasis on TSP-1's role as a matricellular protein that modulates TGF-β signaling...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...